why choose us

300×250 Ad Slot

Research Article: Young patients show poor efficacy for immune checkpoint inhibitor combined therapy in metastatic gastrointestinal cancers

Date Published: 2023-05-03

Abstract:
Background: The impact of age on the efficacy and safety of immunotherapy remains controversial. The previous studies simply classified patients into younger and older groups, which might not reflect the real impact of young age on immunotherapy efficacy. The current study aimed to explore the efficacy and safety of immune checkpoint inhibitor (ICI) combined therapy in young (aged 18–44 years), middle-aged (aged 45–65 years), and old (aged >65 years) patients with metastatic gastrointestinal cancers (GICs), and further determine the role of immunotherapy in young patients.

No summary available.

300×250 Ad Slot